​

CELLASTRA INC.

02/06/2024

Cellastra Receives US Patent for Recombinant Gene Vectors Encoded to Regulate Endogenous Production of Anti-Scarring/Adhesion Lactoferrin Biomolecules.

​​​​

San Francisco, CA, February 06, 2024. Cellastra Inc. (Cellastra or “the Company”), a developer of novel gene therapy assets, announced today, that the company has been granted US Patent No. 11,891,429, entitled “Methods for regulating endogenous production of lactoferrin and sub-peptides thereof. ” The patent claims describe a recombinant virus vector (RVV) comprising a nucleotide sequence encoding a human lactoferrin protein or a sub-peptide thereof.  LINK 

​​

CELLASTRA INC.

12/26/2023

​Cellastra appoints Brad  Thompson

to Chair, Scientific Advisory Board (SAB),

and Karl Mettinger to Chair (Interim),

Board of Directors.  LINK